The Prognostic and therapeutic value and clinical implications of fibroblast activation protein-α as a novel biomarker in colorectal cancer
Open Access
- 14 June 2023
- journal article
- review article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 21 (1) , 1-17
Abstract
The identification of contributing factors leading to the development of Colorectal Cancer (CRC), as the third fatal malignancy, is crucial. Today, the tumor microenvironment has been shown to play a key role in CRC progression. Fibroblast-Activation Protein-α (FAP) is a type II transmembrane cell surface proteinase expressed on the surface of cancer-associated fibroblasts in tumor stroma. As an enzyme, FAP has di- and endoprolylpeptidase, endoprotease, and gelatinase/collagenase activities in the Tumor Microenvironment (TME). According to recent reports, FAP overexpression in CRC contributes to adverse clinical outcomes such as increased lymph node metastasis, tumor recurrence, and angiogenesis, as well as decreased overall survival. In this review, studies about the expression level of FAP and its associations with CRC patients' prognosis are reviewed. High expression levels of FAP and its association with clinicopathological factors have made as a potential target. In many studies, FAP has been evaluated as a therapeutic target and diagnostic factor into which the current review tries to provide a comprehensive insight.Keywords
This publication has 144 references indexed in Scilit:
- High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosisTumor Biology, 2013
- Colorectal Cancer Cells Activate Adjacent Fibroblasts Resulting in FGF1/FGFR3 Signaling and Increased InvasionThe American Journal of Pathology, 2011
- The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Whole tumor antigen vaccinesSeminars in Immunology, 2010
- Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in miceJournal of Clinical Investigation, 2009
- Effect of fibroblast activation protein and α2-antiplasmin cleaving enzyme on collagen Types I, III, and IVArchives of Biochemistry and Biophysics, 2007
- Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptakeJournal of Clinical Investigation, 2006
- Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein αJournal of Biological Chemistry, 2005
- Seprase Promotes Rapid Tumor Growth and Increased Microvessel Density in a Mouse Model of Human Breast CancerCancer Research, 2004
- Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal CancerOncology Research and Treatment, 2003